The Transatlantic Trade and Investment Partnership (TTIP) agreement currently being negotiated by the EU and the US is expected to lead to significant benefits for Denmark, and the pharmaceutical industry is an important driver in this. It is expected to account alone for up to 40 percent of the total expected increase in Danish exports and up to 20 percent of the total impact on Danish GDP arising from an ambitious TTIP agreement, targeting non-tariff barriers to transatlantic trade in pharmaceuticals.
Today, Martin H. Thelle presents our findings at a conference discussing the EU-US free trade agreement at Christiansborg. Other speakers include the American Ambassador to Denmark, Rufus Gifford. Head of Cabinet, Maria Åsenius, and the Danish Minister for Trade and Development Cooperation, Mogens Jensen.
For further information, please contact Martin H. Thelle